Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1470724

Cover Image

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1470724

Biosimilars Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
PDF (Multi User License)
USD 6400
PDF (Corporate User License)
USD 7400

Add to Cart

The Biosimilars Market report by Persistence Market Research provides an extensive analysis of market dynamics, growth factors, challenges, and emerging trends. It encompasses data and statistics on the market's trajectory from 2024 to 2031, offering insights into the current state and future outlook of the Biosimilars Market.

The global biosimilars market is anticipated to grow at a compound annual growth rate (CAGR) of 14.1% from USD 31.5 billion in 2024 to USD 100.1 billion by 2031.

Key Insights:

  • Estimated Market Size (2024): USD 31.5 Billion
  • Projected Market Size (2031): USD 100.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 14.1%

Biosimilars Market - Report Scope:

Biosimilars are biologic medical products that are highly similar to existing biologic products, also known as reference or originator products. The biosimilars market encompasses a wide range of therapeutic categories, including oncology, autoimmune diseases, diabetes, and infectious diseases, among others. The report outlines key drivers behind the demand for biosimilars, including cost-effectiveness, patent expiries of biologic drugs, and increasing demand for affordable treatment options. Moreover, advancements in biotechnology, manufacturing processes, and regulatory pathways drive market growth by facilitating the development, approval, and commercialization of biosimilar products.

Market Growth Drivers:

The market's growth is propelled by several factors. Firstly, the need for cost-effective alternatives to expensive biologic drugs drives demand for biosimilars, offering significant cost savings for patients, healthcare providers, and payers. Additionally, patent expiries of blockbuster biologic drugs create opportunities for biosimilar manufacturers to enter the market and offer affordable alternatives, driving market competition and access to essential therapies. Moreover, increasing acceptance of biosimilars by healthcare professionals, patients, and regulatory authorities fosters market growth by addressing concerns related to safety, efficacy, and interchangeability with reference biologics.

Market Restraints:

Despite the positive outlook, the Biosimilars Market faces certain challenges. Regulatory complexities, intellectual property issues, and market access barriers may impact the development, approval, and commercialization of biosimilar products, influencing market dynamics and competitive landscape. Moreover, manufacturing complexities, including cell line development, process optimization, and quality control, pose challenges to biosimilar manufacturers in ensuring product comparability and consistency with reference biologics. Additionally, market dynamics such as pricing pressures, reimbursement policies, and market exclusivity rights may impact biosimilar uptake and market penetration, posing challenges to market expansion and profitability.

Market Opportunities:

The Biosimilars Market offers significant opportunities for growth and innovation. Manufacturers can focus on developing biosimilar products for niche therapeutic areas, including rare diseases, orphan drugs, and specialty biologics, addressing unmet medical needs and market gaps. Moreover, strategic partnerships, collaborations, and licensing agreements with biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutions facilitate technology transfer, resource sharing, and knowledge exchange, driving biosimilar development and commercialization. Furthermore, expansion into emerging markets, including Asia Pacific, Latin America, and Middle East & Africa, offers opportunities for market expansion and portfolio diversification, tapping into growing demand for affordable biologic therapies and expanding patient populations.

Key Questions Addressed in the Report:

  • What is the Expected CAGR of the Biosimilars Market from 2024 to 2031?
  • What are the Key Factors Driving the Growth of the Biosimilars Market?
  • Which Therapeutic Category Holds the Largest Market Share in the Biosimilars Market?
  • Who are the Key Players in the Global Biosimilars Market?
  • What Strategies are Adopted by Leading Companies to Stay Competitive in the Biosimilars Market?

Competitive Landscape and Business Strategies:

Key players in the Biosimilars Market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Biocon Limited. These companies focus on product development, regulatory strategies, and market access initiatives to differentiate themselves in the market and gain a competitive edge. For instance, Amgen Inc. is known for its biosimilar portfolio, including products such as Neupogen (filgrastim) biosimilar, while Pfizer Inc. specializes in biosimilar versions of blockbuster biologic drugs such as Humira (adalimumab). Market players also invest in research and development, manufacturing capabilities, and global expansion to enhance their biosimilar pipelines, address market needs, and capture market share in key therapeutic categories and geographic regions.

Key Companies Profiled:

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Biocon Limited

Biosimilars Market Segmentation:

By Product Type:

  • Recombinant Glycosylated Proteins
  • Recombinant Non-Glycosylated Proteins

By Application:

  • Hematology
  • Growth Hormone Deficiency
  • Oncology
  • Diabetes Autoimmune
  • Disease
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia and Pacific
  • East Asia
  • Middle East and Africa
Product Code: PMRREP2782

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Technology Roadmap
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Strategic Promotional Strategies

5. Global Biosimilars Market Demand Analysis 2019-2023 and Forecast, 2024-2031

  • 5.1. Historical Market Volume (Tons) Analysis, 2019-2023
  • 5.2. Current and Future Market Volume (Tons) Projections, 2024-2031
  • 5.3. Y-o-Y Growth Trend Analysis

6. Global Biosimilars Market - Pricing Analysis

  • 6.1. Regional Pricing Analysis By Product Type
  • 6.2. Global Average Pricing Analysis Benchmark

7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Market Background

  • 8.1. Macro-Economic Factors
    • 8.1.1. Global GDP Growth Outlook
    • 8.1.2. Global Industry Value Added Overview
    • 8.1.3. Global Infrastructure Investment Overview
    • 8.1.4. Global Construction Spending Analysis
    • 8.1.5. Other Macro Economic Factors
  • 8.2. Forecast Factors - Relevance & Impact
    • 8.2.1. Top Companies Historical Growth
    • 8.2.2. GDP Growth forecast
    • 8.2.3. Construction Industry forecast
    • 8.2.4. Distribution Channel Growth Outlook
    • 8.2.5. Collaboration Activities
  • 8.3. Value Chain
    • 8.3.1. Raw Material Suppliers
    • 8.3.2. List of Manufacturers
    • 8.3.3. List of Distributors
  • 8.4. COVID-19 Crisis - Impact Assessment
    • 8.4.1. Current Statistics
    • 8.4.2. Short-Mid-Long Term Outlook
    • 8.4.3. Likely Rebound
  • 8.5. Market Dynamics
    • 8.5.1. Drivers
    • 8.5.2. Restraints
    • 8.5.3. Opportunity Analysis
    • 8.5.4. Trends

9. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, by Product Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product Type 2024-2031
    • 9.3.1. Recombinant Glycosylated Proteins
    • 9.3.2. Recombinant Non-Glycosylated Proteins
  • 9.4. Market Attractiveness Analysis by Product Type

10. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, By Application

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2024-2031
    • 10.3.1. Hematology
    • 10.3.2. Growth Hormone Deficiency
    • 10.3.3. Oncology
    • 10.3.4. Diabetes Autoimmune
    • 10.3.5. Disease
    • 10.3.6. Others
  • 10.4. Market Attractiveness Analysis By Application

11. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2024-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Online Pharmacies
    • 11.3.3. Retail Pharmacies
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2019-2023
  • 12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2024-2031
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia and Pacific
    • 12.3.6. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
  • 13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
    • 13.4.1. By Country
      • 13.4.1.1. U.S.
      • 13.4.1.2. Canada
    • 13.4.2. By Type
    • 13.4.3. By Application
    • 13.4.4. By Distribution Channel
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Type
    • 13.5.3. By Application
    • 13.5.4. By Distribution Channel
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. Latin America Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
  • 14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
    • 14.4.1. By Country
      • 14.4.1.1. Brazil
      • 14.4.1.2. Mexico
      • 14.4.1.3. Rest of Latin America
    • 14.4.2. By Type
    • 14.4.3. By Application
    • 14.4.4. By Distribution Channel
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Type
    • 14.5.3. By Application
    • 14.5.4. By Distribution Channel
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. Europe Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Pricing Analysis
  • 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
  • 15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
    • 15.4.1. By Country
      • 15.4.1.1. Germany
      • 15.4.1.2. Italy
      • 15.4.1.3. France
      • 15.4.1.4. U.K.
      • 15.4.1.5. Spain
      • 15.4.1.6. BENELUX
      • 15.4.1.7. Russia
      • 15.4.1.8. Rest of Europe
    • 15.4.2. By Type
    • 15.4.3. By Application
    • 15.4.4. By Distribution Channel
  • 15.5. Market Attractiveness Analysis
    • 15.5.1. By Country
    • 15.5.2. By Type
    • 15.5.3. By Application
    • 15.5.4. By Distribution Channel
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Pricing Analysis
  • 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
  • 16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
    • 16.4.1. By Country
      • 16.4.1.1. India
      • 16.4.1.2. ASEAN
      • 16.4.1.3. Oceania
      • 16.4.1.4. Rest of South Asia & Pacific
    • 16.4.2. By Type
    • 16.4.3. By Application
    • 16.4.4. By Distribution Channel
  • 16.5. Market Attractiveness Analysis
    • 16.5.1. By Country
    • 16.5.2. By Type
    • 16.5.3. By Application
    • 16.5.4. By Distribution Channel
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. East Asia Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction
  • 17.2. Pricing Analysis
  • 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
  • 17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
    • 17.4.1. By Country
      • 17.4.1.1. China
      • 17.4.1.2. Japan
      • 17.4.1.3. South Korea
    • 17.4.2. By Type
    • 17.4.3. By Application
    • 17.4.4. By Distribution Channel
  • 17.5. Market Attractiveness Analysis
    • 17.5.1. By Country
    • 17.5.2. By Type
    • 17.5.3. By Application
    • 17.5.4. By Distribution Channel
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Biosimilars Market Analysis 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction
  • 18.2. Pricing Analysis
  • 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
  • 18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
    • 18.4.1. By Country
      • 18.4.1.1. GCC Countries
      • 18.4.1.2. Turkey
      • 18.4.1.3. Northern Africa
      • 18.4.1.4. South Africa
      • 18.4.1.5. Rest of Middle East and Africa
    • 18.4.2. By Type
    • 18.4.3. By Application
    • 18.4.4. By Distribution Channel
  • 18.5. Market Attractiveness Analysis
    • 18.5.1. By Country
    • 18.5.2. By Type
    • 18.5.3. By Application
    • 18.5.4. By Distribution Channel
  • 18.6. Market Trends
  • 18.7. Key Market Participants - Intensity Mapping
  • 18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Biosimilars Market Analysis

  • 19.1. Introduction
    • 19.1.1. Market Value Proportion Analysis, By Key Countries
    • 19.1.2. Global Vs. Country Growth Comparison
  • 19.2. U.S. Biosimilars Market Analysis
    • 19.2.1. By Type
    • 19.2.2. By Application
    • 19.2.3. By Distribution Channel
  • 19.3. Canada Biosimilars Market Analysis
    • 19.3.1. By Type
    • 19.3.2. By Application
    • 19.3.3. By Distribution Channel
  • 19.4. Mexico Biosimilars Market Analysis
    • 19.4.1. By Type
    • 19.4.2. By Application
    • 19.4.3. By Distribution Channel
  • 19.5. Brazil Biosimilars Market Analysis
    • 19.5.1. By Type
    • 19.5.2. By Application
    • 19.5.3. By Distribution Channel
  • 19.6. Germany Biosimilars Market Analysis
    • 19.6.1. By Type
    • 19.6.2. By Application
    • 19.6.3. By Distribution Channel
  • 19.7. Italy Biosimilars Market Analysis
    • 19.7.1. By Type
    • 19.7.2. By Application
    • 19.7.3. By Distribution Channel
  • 19.8. France Biosimilars Market Analysis
    • 19.8.1. By Type
    • 19.8.2. By Application
    • 19.8.3. By Distribution Channel
  • 19.9. U.K. Biosimilars Market Analysis
    • 19.9.1. By Type
    • 19.9.2. By Application
    • 19.9.3. By Distribution Channel
  • 19.10. Spain Biosimilars Market Analysis
    • 19.10.1. By Type
    • 19.10.2. By Application
    • 19.10.3. By Distribution Channel
  • 19.11. BENELUX Biosimilars Market Analysis
    • 19.11.1. By Type
    • 19.11.2. By Application
    • 19.11.3. By Distribution Channel
  • 19.12. Russia Biosimilars Market Analysis
    • 19.12.1. By Type
    • 19.12.2. By Application
    • 19.12.3. By Distribution Channel
  • 19.13. China Biosimilars Market Analysis
    • 19.13.1. By Type
    • 19.13.2. By Application
    • 19.13.3. By Distribution Channel
  • 19.14. Japan Biosimilars Market Analysis
    • 19.14.1. By Type
    • 19.14.2. By Application
    • 19.14.3. By Distribution Channel
  • 19.15. S. Korea Biosimilars Market Analysis
    • 19.15.1. By Type
    • 19.15.2. By Application
    • 19.15.3. By Distribution Channel
  • 19.16. India Biosimilars Market Analysis
    • 19.16.1. By Type
    • 19.16.2. By Application
    • 19.16.3. By Distribution Channel
  • 19.17. ASEAN Biosimilars Market Analysis
    • 19.17.1. By Type
    • 19.17.2. By Application
    • 19.17.3. By Distribution Channel
  • 19.18. Australia and New Zealand Biosimilars Market Analysis
    • 19.18.1. By Type
    • 19.18.2. By Application
    • 19.18.3. By Distribution Channel
  • 19.19. GCC Countries Biosimilars Market Analysis
    • 19.19.1. By Type
    • 19.19.2. By Application
    • 19.19.3. By Distribution Channel
  • 19.20. Turkey Biosimilars Market Analysis
    • 19.20.1. By Type
    • 19.20.2. By Application
    • 19.20.3. By Distribution Channel
  • 19.21. Northern Africa Biosimilars Market Analysis
    • 19.21.1. By Type
    • 19.21.2. By Application
    • 19.21.3. By Distribution Channel
  • 19.22. South Africa Biosimilars Market Analysis
    • 19.22.1. By Type
    • 19.22.2. By Application
    • 19.22.3. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.1.4. Sales Footprint
      • 21.3.1.5. Strategy Overview
    • 21.3.2. Sandoz International GMBH
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.2.4. Sales Footprint
      • 21.3.2.5. Strategy Overview
    • 21.3.3. Eli Lily & Company
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.3.4. Sales Footprint
      • 21.3.3.5. Strategy Overview
    • 21.3.4. Hospira Inc.
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.4.4. Sales Footprint
      • 21.3.4.5. Strategy Overview
    • 21.3.5. Amgen, Inc.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.5.4. Sales Footprint
      • 21.3.5.5. Strategy Overview
    • 21.3.6. Biocon Ltd.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.6.4. Sales Footprint
      • 21.3.6.5. Strategy Overview
    • 21.3.7. Actavis, Inc.
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.7.4. Sales Footprint
      • 21.3.7.5. Strategy Overview
    • 21.3.8. Cipla Ltd.
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.8.4. Sales Footprint
      • 21.3.8.5. Strategy Overview
    • 21.3.9. Teva Pharmaceutical Industries, Ltd.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.9.4. Sales Footprint
      • 21.3.9.5. Strategy Overview
    • 21.3.10. Dr. Reddy's Laboratories Ltd.
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.10.4. Sales Footprint
      • 21.3.10.5. Strategy Overview
    • 21.3.11. Celltrion, Inc.
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.11.4. Sales Footprint
      • 21.3.11.5. Strategy Overview
    • 21.3.12. Stada Arzeimittel Ag
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.12.4. Sales Footprint
      • 21.3.12.5. Strategy Overview
    • 21.3.13. Mylan, Inc.
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.13.4. Sales Footprint
      • 21.3.13.5. Strategy Overview
    • 21.3.14. Wockhardt Ltd.
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.14.4. Sales Footprint
      • 21.3.14.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!